Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
· phd, md, alice shaw
AI Briefing
- • Lorlatinib maintains controlled ALK+ non-small cell lung cancer after 7 years.
- • Lorlatinib shows durable brain protection in advanced ALK+ lung cancer patients.
- • Lorlatinib's safety remains stable over 7 years of treatment.
Context
Lorlatinib is showing effectiveness in controlling ALK+ lung cancer, according to 7-year data. The treatment provides durable brain protection and has stable safety.
The 7-year update from the phase 3 CROWN study offers insights into lorlatinib's long-term performance compared to crizotinib as a first-line treatment for advanced ALK+ non-small cell lung cancer.
Advertisement